Recent shortages of essential antibiotics in Europe have renewed the urgency to reform the pricing and industrial infrastructure for these essential medicines. The off-patent sector manufactures and supplies most antibiotics in Europe needed to control bacterial infections. Pricing policies for these antibiotics must urgently be reviewed so that they remain viable to produce and supply.

Open